Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ACP1 | P24666 | 2/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | RHOC | P08134 | 2/20 | 0.38 |
| ▸ | RHOA | P61586 | 2/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.38 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12005795 | 0.91 | CXCR3 (0.50) | LMNAALDH1A1ACP1CXCR3NAMPT | |
| SCHEMBL12004810 | 0.90 | CXCR3 (0.53) | LMNAALDH1A1ACP1CXCR3MAPT | |
| SCHEMBL6863055 | 0.82 | CACNA1H (0.52) | LMNAALDH1A1ACP1CXCR3MAPT | |
| SCHEMBL1444731 | 0.81 | LMNA (0.50) | LMNAALDH1A1ACP1CXCR3MAPT | |
| SCHEMBL6863428 | 0.81 | TACR1 (0.48) | LMNAALDH1A1ACP1CXCR3MAPT | |
| SCHEMBL4277997 | 0.78 | CXCR3 (0.55) | LMNAALDH1A1ACP1CXCR3MAPT | |
| SCHEMBL6863165 | 0.77 | CXCR3 (0.47) | LMNAALDH1A1ACP1CXCR3NAMPT | |
| SCHEMBL4278127 | 0.76 | CXCR3 (0.56) | LMNAALDH1A1ACP1CXCR3MAPT | |
| SCHEMBL1444654 | 0.75 | STS (0.52) | CXCR3MAPTTACR1RHOCRHOA | |
| SCHEMBL12004818 | 0.75 | NAMPT (0.44) | LMNAALDH1A1ACP1CXCR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | LMNA 847/4885ALDH1A1 2690/4885ACP1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.